Next Article in Journal
Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
Previous Article in Journal
Correction: McCart Reed et al. The Genomic Landscape of Lobular Breast Cancer. Cancers 2021, 13, 1950
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 13
Issue 16
10.3390/cancers13164011
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells

by
Grazia Carbotti
1,†,
Beatrice Dozin
2,†,
Stefania Martini
3,
Chiara Giordano
1,
Francesca Scordamaglia
4,
Michela Croce
1,
Gilberto Filaci
1,5,
Silvano Ferrini
1,6,* and
Marina Fabbi
1,*
1
Biotherapies Unit, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy
2
Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy
3
Immunology Unit, IRCCS Ospedale Policlinico San Martino, Largo R. Benzi 10, 16132 Genoa, Italy
4
Department of Pneumology, Azienda Ospedaliera Villa Scassi, Corso O. Scassi 1, 16149 Genoa, Italy
5
Centre of Excellence for Biomedical Research and Department of Internal Medicine, University of Genoa, Via De Toni 14, 16132 Genoa, Italy
6
Department of Experimental Medicine, University of Genoa, Via L.B. Albertis 2, 16132 Genoa, Italy
*
Authors to whom correspondence should be addressed.
†
Equal contributors.
Cancers 2021, 13(16), 4011; https://doi.org/10.3390/cancers13164011
Submission received: 1 July 2021 / Revised: 2 August 2021 / Accepted: 5 August 2021 / Published: 9 August 2021
Browse Figures
Versions Notes

Abstract

:

Simple Summary

Malignant mesothelioma (MM), a rare and aggressive tumor, is related to asbestos exposure, which mediates a chronic inflammatory process involving the cytokine IL-6. Recent studies indicate that the PD-1/PD-L1 immune-suppressive axis is a clinically relevant target for therapy. The expression of PD-L1 in tumor cells is generally a cytokine-mediated effect. Here we show that the IL-6-related cytokine IL-27 is able to enhance PD-L1 expression and soluble (s)PD-L1 release by cultured MM cells, whereas IL-6 is ineffective. In agreement with previous findings, we found high IL-6 levels in pleural exudates from 77 MM patients which correlated with worse survival. More importantly, we also found sPD-L1 and IL-27 in the same samples. sPD-L1 and IL-27 levels showed a moderate albeit significant correlation and association with worse survival, which suggested a potential effect of IL-27 on PD-L1-mediated immune resistance in MM.

Abstract

Malignant mesothelioma (MM) is a rare tumor with an unfavorable prognosis. MM genesis involves asbestos-mediated local inflammation, supported by several cytokines, including IL-6. Recent data showed that targeting PD-1/PD-L1 is an effective therapy in MM. Here, we investigated the effects of IL-6 trans-signaling and the IL-6-related cytokine IL-27 on human MM cells in vitro by Western blot analysis of STAT1/3 phosphorylation. The effects on PD-L1 expression were tested by qRT-PCR and flow-cytometry and the release of soluble (s)PD-L1 by ELISA. We also measured the concentrations of sPD-L1 and, by multiplexed immunoassay, IL-6 and IL-27 in pleural fluids obtained from 77 patients in relation to survival. IL-27 predominantly mediates STAT1 phosphorylation and increases PD-L1 gene and surface protein expression and sPD-L1 release by human MM cells in vitro. IL-6 has limited activity, whereas a sIL-6R/IL-6 chimeric protein mediates trans-signaling predominantly via STAT3 phosphorylation but has no effect on PD-L1 expression and release. IL-6, IL-27, and sPD-L1 are present in pleural fluids and show a negative correlation with overall survival, but only IL-27 shows a moderate albeit significant correlation with sPD-L1 levels. Altogether these data suggest a potential role of IL-27 in PD-L1-driven immune resistance in MM.

1. Introduction

Malignant mesothelioma (MM) is a rare tumor arising from the mesothelial cells underlining the pleural, peritoneal, or, less frequently, pericardial cavities. In spite of aggressive treatments including surgery, radiotherapy, and/or chemotherapy, the prognosis of MM remains poor, with a median overall survival of about 15 months [1]. Immunotherapy with the anti-CTLA-4 mAb tremelimumab has shown no impact on survival when administered as a second- or third-line therapy in MM patients [2]. However, immunotherapy with anti-PD-1 or anti-PD-L1 mAbs alone or in combination with anti-CTLA-4 mAbs showed promising activity in relapsing MM patients [3,4,5,6,7,8,9]. More importantly, a recent phase III study showed that the combination of nivolumab and ipilimumab improved overall survival versus standard-of-care chemotherapy in unresectable MM [10]. These data support a role for the PD-1/PD-L1 interaction as a clinically relevant immune-suppressive mechanism in MM. Indeed, high PD-L1 expression in MM tissues correlates with a more severe prognosis [11,12].
MM genesis is strictly linked to asbestos fiber exposure, which causes necrotic cell death and the release of the high mobility group box protein-1 (HMGB1) [13]. In turn, HMGB1 acts as a danger signal triggering the NALP3 inflammasome, which induces a chronic inflammatory response via secretion of TNF and IL-1β by macrophages [14,15]. Several other cytokines and chemokines are then involved in this chronic inflammatory process [16,17]. In particular, auto/paracrine IL-6 has been reported to play a major role in MM [18] as its concentration is elevated in MM sera and pleural fluids [19,20].
IL-6 signals through a membrane heterodimer receptor consisting of the IL-6R and GP130 chains. Besides this classical signaling, IL-6 can also bind to a soluble (s) form of IL-6R, and this complex can mediate trans-signaling in cells expressing the GP130 chain, irrespective of surface IL-6R expression [21]. A previous study supported a role for IL-6 trans-signaling in promoting MM cell proliferation and VEGF production in vitro [22]. IL-6 was also reported to induce PD-L1 expression in myeloid cells in a murine glioblastoma model [23] and in human myeloma cells [24].
IL-6 is part of a large family of cytokines, including IL-27, which share the usage of a common GP130 receptor chain in their receptor complexes [25,26]. Whereas IL-6 has mainly pro-tumor activities, IL-27 may have a dual biological role in different cancers [27]. IL-27 is also a member of the IL-12 family of heterodimer cytokines [28,29]. It consists of p28 and EBI3 chains and binds to a heterodimer receptor consisting of GP130 and WSX1 [30].
IL-27 induces a set of proteins broadly overlapping with those induced by IFN-γ [31] and shares several anti-tumor functions in common with IFNs, including anti-angiogenic activities [32], induction of HLA-class I molecule expression [33,34,35], and anti-proliferative activity on cancer cells [36,37]. In addition, similar to IFN-γ [38,39], it also mediates the expression of PD-L1 and the immune-suppressive enzyme IDO in cancer cells [40]. Therefore, both IFN-γ and IL-27 induce immune-regulatory circuits, which may limit anti-tumor immunity. In a recent report, we found that high IFN-γ levels in pleural exudate correlate with better prognosis in a cohort of MM patients presenting mostly a stage I-II tumor [41]. However, IFN-γ levels were lower and showed no association with prognosis in a different cohort of MM patients with advanced-stage disease.
In the present study, we first addressed the effects of IL-27 on MM cell lines in vitro. In addition, we tested the effects of IL-6 and IL-6 trans-signaling through a sIL-6R/IL-6 chimeric protein, mimicking the sIL-6R/IL-6 complex. Interestingly, IL-27 increased PD-L1 surface expression and soluble (s)PD-L1 secretion in MM cell lines, supporting a potential role of IL-27 in inducing PD-1/PD-L1 immune-suppressive circuits. We thus measured the levels of immune-reactive IL-6, IL-27, and sPD-L1 in MM pleural fluids and assessed whether these factors correlated with survival in a cohort of 77 MM patients.

2. Results

2.1. IL-27 and a sIL-6R/IL-6 Chimeric Protein Mediated Signal Transduction in Human MM Cells

To assess the responsiveness of MM cells to IL-27 and other related cytokines of the IL-12 family, we treated MPP89 cells and performed Western blot analysis of tyrosine-phosphorylated STAT1 and STAT3 proteins (Figure 1A). We tested a panel of cytokines sharing one of the two chains (p28 or EBI3) with IL-27, i.e., EBI3, IL-12, IL-23, IL-30, and IL-35. In addition, we also tested IL-6 and a sIL-6R/IL-6 chimeric protein, capable of mediating IL-6 trans-signaling.
As shown in Figure 1A, the MMP89 cell line responded to sIL-6R/IL-6 through STAT3 and STAT1 phosphorylation, while IL-27 predominantly induced STAT1 activation. By contrast, IL-6 and the IL-27-related cytokines EBI3, IL-12, IL-23, IL-30, and IL-35 failed to trigger STAT1/3 signal transduction.
Consistent results were obtained with the other two MM cell lines, MSTO and IST-MES1, of which only one (IST-MES1) also weakly responded to IL-6, whereas all cell lines phosphorylated STAT3 and to a lesser extent STAT1 in response to sIL-6R/IL-6 stimulation (Figure 1B). Overall, IL-27 predominantly induced STAT1 phosphorylation and a weaker phosphorylation of STAT3 as compared to the sIL-6R/IL-6 chimeric protein. As expected, stimulation with IFN-γ predominantly triggered STAT1 phosphorylation in MM cell lines similar to IL-27 (Supplementary Materials Figure S1).

2.2. IL-27, but Not sIL-6R/IL-6 Chimeric Protein, Mediates Expression of Surface PD-L1 Molecule and Release of Soluble PD-L1 by MM Cells

Results of clinical studies with anti-PD-1/PD-L1 immune checkpoint blockers supported the relevance of this immune regulatory pathway in MM [10]. Since IL-27 can induce PD-L1 expression in different tumor cell types [40], we assessed IL-27’s capability of upregulating PD-L1 expression in human MM cell lines as compared to the sIL-6R/IL-6 chimera.
Cytofluorimetric analyses indicate that IL-27 induced an average three-fold increase in surface PD-L1 expression relative to constitutive expression, in the three MM cell lines tested. By contrast, IL-6 and sIL-6R/IL-6 chimera failed to modulate surface PD-L1 expression (Figure 2A). Notably, two out of three cell lines showed constitutive expression of surface PD-L1 relative to isotype Ig control. In a second set of experiments, we compared the effect of IL-27 with that of IFN-γ, which is a known inducer of PD-L1 [39,42,43], and found that both stimuli mediated PD-L1 cell surface upregulation (Supplementary Materials Figure S2A).
Consistently, expression of CD274 (PD-L1) mRNA was enhanced by IL-27 or IFN-γ treatment, whereas the IL-6 and sIL-6R/IL-6 induced no or minor changes in the MM cell lines tested (Figure 2B). As a control of IL-27 or IFN-γ activity, we assessed the expression levels of the GBP1 gene, which is upregulated by both cytokines [44].
Recent data indicated that IFN-γ is capable of mediating not only PD-L1 surface expression but also soluble (s)PD-L1 release by human MM cells [45]. We, therefore, assessed whether IL-27 may have similar effects. As shown in Figure 2C, IL-27 triggered sPD-L1 release from two out of three MM cell lines. By contrast, IL-6 or sIL-6R/IL-6 chimera failed to induce sPD-L1 release.
Since IL-27 is known to upregulate surface HLA Class I expression in different types of human cancer cells [31,33,34,35], we assessed whether this effect also occurred in MM cells. As shown in Supplementary Materials Figure S2B, human MM cells constitutively expressed surface HLA Class I heavy chains in complex with β2-microglobulin, as detected by the W6/32 mAb, in agreement with previous findings [46,47,48]. IL-27 further enhanced cell surface expression of HLA Class I/β2-microglobulin complexes, while sIL-6R/IL-6 chimeric protein was ineffective in this respect.

2.3. Immuno-Reactive IL-27 Is Detectable in MM Pleural Exudates and Correlates with Soluble PD-L1 Expression

To gain information on the potential role of IL-27 and IL-6 in MM in vivo and their possible relationship with sPD-L1, we assessed the levels of these molecules by Luminex or ELISA assays in MM pleural fluids. We detected sPD-L1 (median value 166.2 pg/mL, minimum 61.5, maximum 1154.1), IL-27 (median 357.9 pg/mL, min. 44.9, max. 1698) and IL-6 (median 1683 pg/mL, min. 113.9, max. 4003) at variable levels in a cohort of 77 MM cases (Figure 3A).
Interestingly, IL-27 levels showed a moderate (R = 0.3781) albeit highly significant (p = 0.0007) correlation with sPD-L1 levels, suggestive of a potential role for IL-27 in PD-L1 upregulation in vivo (Figure 3B).
This observation was confirmed using a binomial logistic regression (Table 1).
As can be seen, patients with high IL-27 concentrations were almost five times more likely to exhibit high concentrations of sPD-L1 as compared to patients with low IL-27 concentrations (OR = 4.86, 95% CI 1.86–12.79, p = 0.001). By contrast, both low and high concentrations of IL-6 correlated to the same extent with high concentrations of sPD-L1 (OR = 0.95, 95% CI 0.39–2.32, p = 0.910).
Altogether, these data indicated a potential role for IL-27 in PD-L1-mediated immune resistance in MM. Since PD-L1 expression in mesothelioma cells is induced by IFN-γ in vitro, we also investigated the possible correlation between sPD-L1 and IFN-γ concentrations in pleural fluids in our patients’ cohort. To this end, we first re-assessed IFN-γ in the same samples by a high-sensitivity ELISA kit, as our previous results showed that IFN-γ levels were below the threshold sensitivity of the Luminex assay [41]. Here we confirmed the presence of overall low levels of IFN-γ (median value 0.884 pg/mL, min. 0.001, max. 31.47), which showed a moderate but significant correlation with sPD-L1 concentrations and a weaker correlation with IL-27 levels (Supplementary Materials Figure S3).

2.4. Overall Survival According to PD-L1, IL-27, and IL-6 Concentrations in the Pleural Effusion

After the withdrawal of the pleural effusion sample, the 77 patients included in the study were followed for a median period of 42.2 months (95% CI 21.6–62.9). During this time frame, 66 of them (87.0%) died. Median overall survival (OS) was 10.4 months (95% CI 8.0–12.8).
For all three factors analyzed, a concentration below the median value favored OS. This effect was particularly significant for sPD-L1 and IL-6 and somehow less pronounced for IL-27.
Specifically, median OS was 13.4 months (95% CI 9.4–17.5) for low sPD-L1 concentrations as compared to 7.5 months (95% CI 1.7–13.3) for high sPD-L1 concentrations (p = 0.011) (Figure 4, panel A). Similarly, survival was significantly better in patients with low IL-6 levels as compared to patients with high IL-6 levels (median OS 13.4 months (95% CI 11.3–15.5) vs. 8.6 months (95% CI 6.3–10.9, p = 0.001) (Figure 4, panel B). By contrast, IL-27 concentration did not significantly affect OS, the median values being 10.5 months (95% CI 6.4–14.6) and 9.1 months (95% CI 6.4–11.8) for low and high concentrations, respectively (p = 0.111) (Figure 4, panel C).
Most of the patients (n = 55) presented epithelioid mesothelioma. In this subgroup, the risk of death was reduced by almost 70% as compared to that of patients with other histotypes (HR = 0.31, 95% CI 0.18–5.4, p < 0.001; not shown). As in the whole cohort, OS was favored in this subgroup in the presence of low levels of sPD-L1 and IL-6 in the pleural effusion as compared to high levels: sPD-L1, 16.6 months (95% CI 7.0–26.2) vs. 10.5 months (95% CI 5.8–15.2), p = 0.018, Figure 4, panel D; IL-6, 27.2 months (95% CI 9.2–45.1) vs. 8.9 months (95% CI 5.3–12.5), p = 0.001, Figure 4, panel E. Moreover, IL-27 at low concentration also improved survival in the epithelioid subgroup with respect to high concentration (16.6 months (95% CI 0.7–33.5) vs. 9.1 months (95% CI 5.1–13.1), p = 0.009, Figure 4, panel F).
Finally, IFN-γ concentration measured by high-sensitivity ELISA did not significantly affect OS, the median OS values being 10.1 months (95% CI 6.4–13.8) and 10.4 months (95% CI 7.3–13.7) for low and high concentrations, respectively (p = 0.858). The same was true in the subgroup of patients presenting an epithelioid subtype (respective median OS were 11.5 and 13.4 months for low and high IFN-γ concentrations, p = 0.928) (Supplementary Materials Figure S3). Despite the lack of effect of IFN-γ on survival, we found that sPD-L1 concentrations significantly correlated with IFN-γ concentrations, as determined by a binomial logistic regression. Patients with high levels of IFN-γ were more than five times more likely to exhibit high levels of sPD-L1 as compared to patients with low IFN-γ levels (OR = 5.16, 95% CI 1.62–16.39, p = 0.005).

3. Discussion

It is well known that pro-inflammatory cytokines play a crucial role in human MM pathogenesis, progression, angiogenesis, resistance to therapy, and immune escape mechanisms [13,14,15,16,17,18]. In particular, cytokines, such as IFN-γ, released during T cell responses, upregulate the expression of PD-L1 on the tumor cell surface, thus inhibiting further activation of CTLs responses. This phenomenon has been reported as “adaptive immune resistance” [38,39,49,50] and is a major mechanism of immune escape in several tumors, as evidenced by the successful results of anti-PD-1/PD-L1 antibodies in cancer immunotherapy [38,49].
Recent reports indicated that IFN-γ upregulates membrane PD-L1 expression and soluble (s)PD-L1 release in human mesothelioma cells in vitro [43]. Therefore, adaptive immune resistance could represent a major mechanism of tumor escape and a target for therapy in human MM. Indeed, a recent randomized trial evaluating the combination of anti-PD-1 and anti-CTLA4 as first-line immunotherapy supports a role for the PD-1/PD-L1 interaction as a clinically relevant immune regulatory mechanism in MM [10]. Furthermore, sPD-L1 is found in the pleural effusion of mesothelioma patients in relationship with the PD-L1 expression at the level of the tumoral tissue [45].
Since we recently found that IFN-γ levels were very low in pleural exudates of advanced-stage MM [41], we wondered whether IL-27 could be involved in PD-L1 upregulation and release in advanced MM. Indeed, in a previous study, we showed that IL-27, a cytokine produced by macrophages or DCs, may provide an alternative stimulus for PD-L1 expression in different types of human cancer cells [40]. In the present study, we first demonstrated that MM cells responded to IL-27 by inducing STAT1 phosphorylation and, to a lesser extent, STAT3 activation in vitro, whereas other members of the IL-12-cytokine family were ineffective. Regarding the biological effects of IL-27 signaling on MM cells, we found that it upregulated the surface expression of HLA Class I molecules. However, since HLA Class I is already abundant on MM cells, such an effect could have a minor impact on MM immune recognition by CTLs. On the other hand, similar to IFN-γ [45], IL-27 increased surface PD-L1 expression, CD274 (PD-L1) mRNA levels, and sPD-L1 release in MM cells, suggesting that it may promote a negative effect on T cell responses. Besides the induction of PD-L1 expression in tumor cells, IL-27 may have additional immune-suppressive activities through the induction of IL-10-producing or PD-L1-expressing regulatory-type CD4+ T cells, such as described in autoimmunity and GVHD models [51,52,53,54,55]. Whether these activities are relevant to immune regulation and disease progression in MM remains to be determined.
In addition to IL-27, we also studied IL-6, another cytokine involved in immune regulation, which may play a major role in MM oncogenesis and progression [18]. We here showed that IL-6 failed to trigger the signaling cascade in MM cells unless complexed with soluble (s)IL-6R. Indeed, a chimeric protein mimicking the sIL-6R/IL-6 complex mediated trans-signaling mainly through STAT3 phosphorylation and a weaker STAT1 activation. These data are consistent with a previous report showing that IL-6 is able to mediate signaling in human MM cells only in the presence of sIL-6R, as MM cells lack surface expression of the IL-6R chain [22]. Although sIL-6R/IL-6 complexes mediated IL-6 trans-signaling in MM cells in vitro, this signaling did not result in increased PD-L1 expression in the MM cell panel tested.
We then verified the potential impact of IL-27 in the MM microenvironment by cytokine quantification in pleural fluids from a cohort of 77 MM patients. IL-27 was well detected within the standard curve range of values in all samples, indicating that it may play a role in vivo in MM. Moreover, high IL-27 levels were significantly associated with worse survival in the epithelioid MM subgroup of cases.
We also found that sPD-L1 was present in the same pleural exudates, in agreement with a previous report in a different MM cohort [45]. In addition, high sPD-L1 levels were significantly associated with worse survival in our cohort. Importantly, we found a moderate, albeit highly significant, correlation between IL-27 and sPD-L1 levels, which suggested a potential role for IL-27 in the activation of PD-L1/PD-1-mediated immune-regulatory pathway in advanced stage MM. In addition to IL-27, IFN-γ levels also showed a similar correlation with sPD-L1 in pleural exudates, suggesting that both IL-27 and IFN-γ may contribute to PD-L1 expression in the mesothelioma microenvironment. In addition, the low but significant correlation between IL-27 and IFN-γ concentration suggests a potential interplay between the two cytokines in a subset of patients. Previous data indicated that sPD-L1 may derive either from metalloprotease-mediated shedding of cell surface PD-L1 molecules [56,57] or from CD274 mRNA alternative splicing, which generates a dimeric form of PD-L1 [58]. Both sPD-L1 forms were capable of binding surface PD-1 on T cells and mediated immune suppression [59,60]. Soluble PD-L1 may also interfere with immunotherapy with PD-L1-blocking mAbs as it competes with membrane PD-L1 [61,62,63] and impairs the anti-PD-L1-mediated antibody-dependent cellular cytotoxicity (ADCC) of MM cells. In this context, it was reported that MM cells are sensitive to anti-PD-L1 mAb-mediated ADCC [64,65].
Several reports indicated that IL-27 may play a dual role in cancer biology and immunotherapy [27,29,66]. Overall, the correlation between high IL-27 levels and worse survival in the epithelioid MM subgroup together with IL-27 ability to drive upregulation of membrane and sPD-L1 expression in vitro and the correlation between sPD-L1 and IL-27 in vivo support a pro-tumor, immune-suppressive role for IL-27 in advanced MM.
In agreement with previous data [18], we found that IL-6 was present at high concentrations in the pleural effusion of MM and correlated with a worse prognosis. More importantly, we found that high levels of sIL-6R were present in the same fluids (not shown), supporting the role of sIL-6R/IL-6 complexes as mediators of IL-6 trans-signaling in vivo in human MM.
In spite of the common negative impact of IL-6 and IL-27 levels on survival, the concentrations of the two cytokines varied independently. The lack of correlation may be related to the only partially overlapping cellular sources of IL-6 and IL-27. Indeed, IL-27 is mainly produced by myelomonocytic cells [27,67], while IL-6 can be secreted by several other cell types, including T lymphocytes and tumor cells [68].
In conclusion, our data indicate that IL-27 is present at meaningful concentrations in MM pleural exudates and may play an immune regulatory role in advanced-stage MM, possibly through the induction of PD-L1 expression.

4. Materials and Methods

4.1. Ethics Approval and Consent to Participate

This study was conducted in accordance with the ethical standards and according to the Declaration of Helsinki and National and International guidelines and has been approved by the authors’ Institutional Review Board (Study n. N9-13, ASL3. Regional platform id 4975). Pleural fluids were collected during surgical procedures from patients who gave written informed consent and were used following the Institutional Review Board approval.

4.2. Cells and Treatments

The human MM cell lines MPP89 and IST-MES1 [48] and MSTO were obtained from Interlab Cell Line Collection (ICLC, Ospedale Policlinico San Martino, Genoa, Italy) and were never cultured for more than 4 months after thawing an aliquot of the original stock. Cells were grown in RPMI 1640, with L-glutamine, 10% FCS, and antibiotics (Lonza) at 37 °C in 5% carbon dioxide. The human cytokines used were: IL-27 (2526-IL-010), IL-6 (206-IL-010), recombinant human IL-6R/IL-6 chimera (8954-SR-025), IL-12 (219-IL-005), and IL-23 (1290-IL-010) from R&D Systems, IFN-γ (PeproTech, 300–02), IL-35 (Enzo Life Sciences, ALX-522-140-C010), IL-30 (Abnova, H00246778-P01), and EBI3 (Novus Biologicals, P4568). Treatments with cytokines were set on the basis of preliminary titration experiments and previous reports [31,35,40,44]. Briefly, for immunofluorescence, RT-PCR, and ELISA of conditioned media, MM cells were seeded in 24-well plates at 5 × 104 cells/well, and cytokines were added for a 48-h treatment: IL-27 at 100 ng/mL, IFN-γ at 1000 IU/mL, IL-6 at 50 ng/mL, or recombinant human IL-6R/IL-6 chimera at 50 ng/mL. For Western blot analysis of tyrosine-phosphorylated STAT proteins, 105 cells were incubated for 20 min at 37 °C in 0.5 mL of medium containing IL-27 (50 ng/mL), IL-6 (20 ng/mL), sIL-6R/IL-6 (40 ng/mL), or IFN-γ (1000 IU/mL). Cells were then recovered by centrifugation and immediately processed.

4.3. Western Blot

Cells were lysed with 20 mM Tris-HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Brij97, 2 mM Na Orthovanadate, and protease inhibitors (Roche Diagnostics, Complete Mini 04693124001). Proteins were resolved by 10% SDS-PAGE under reducing conditions, and Western blotting was carried out according to standard techniques, with rabbit anti-phospho-STAT1 (pY701) and anti-STAT1 anti-sera (Cell Signaling Technology, 9167 and 9172, respectively), mouse anti-phospho-STAT3 (pY705) and anti-STAT3 mAbs (BD Transduction Laboratories, 612,356 and 610,190, respectively) and α-tubulin mAb (Sigma-Aldrich, T6074).
Immunoreactive proteins were detected by ECL Prime (GE Healthcare, RPN2232) and a chemiluminescence gel documentation and analysis system (MINI HD, UVITEC, Cambridge, UK). Densitometric analyses of relevant bands and whole Western blot images are shown in the Supplementary Materials Figure S4.

4.4. Immunofluorescence and Flow Cytometry

Immunofluorescence with anti-PD-L1 PE or Isotype Control PE (eBioscience Bender, BMS-125983-41 and BMS-124724-41, respectively) was performed according to the manufacturer’s instructions. Indirect immunofluorescence with anti-HLA Class I W6/32 mAb (ATCC) and FITC-labeled goat anti-mouse (Jackson Immunoresearch, 115-096-068) was performed on 105 cells/sample following standard procedures. Samples were analyzed by a FACScan (Becton & Dickinson) flow cytometer and the Cell Quest software, with gating on viable cells and acquisition of 104 gated events.

4.5. RT-PCR Analysis

Total RNA was isolated by the NucleoSpin RNA kit (Macherey-Nagel, 740955.250) and reverse-transcribed using the SuperScript III Reverse Transcriptase (Invitrogen, 18064-071). Amplification was carried out using the iQTM SYBR® Green Supermix system (Bio-Rad Laboratories, 170–8882) by the Mastercycler® ep realplex4 instrument (Eppendorf International). Expression levels of mRNAs relative to untreated control were calculated by the ΔΔCT method. The primers used are listed in Supplementary Materials Table S1.

4.6. Cytokine Dosage and ELISA Tests

The concentrations of IL-27 and IL-6 in the MM pleural effusions were assessed with a bead-based multiplexed immunoassay and Luminex technology (MILLIPLEX MAP Human TH17 Magnetic Bead Panel, customized HTH17MAG-8K, Merck Millipore, Darmstadt, Germany), according to the manufacturer’s instructions. Samples were tested both at 1:2 and 1:10 dilutions in Assay Buffer.
The levels of soluble PD-L1 protein were measured by ELISA using the Human PD-L1 [28–8] SimpleStep ELISA Kit (Abcam, ab214565), following datasheet instructions. Both pleural effusions and conditioned media were centrifuged in a microfuge to eliminate debris and used undiluted. Results were processed by the BioTek EL808 absorbance microplate reader and GEN5 Software version 2.03.01.

4.7. Patients

A cohort of 77 MM patients was included in the study with the purpose of assessing survival. See Supplementary Materials Table S2 for clinical characteristics of cases. The cohort was obtained from the “Alessandria Biobank-Centro Raccolta Materiali Biologici”, Department of Integrated Activities Research and Innovation, Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy. These patients were subjected to diagnostic thoracentesis and thoracoscopy between July 2012 and July 2019. During these processes, samples of pleural effusion were withdrawn, debris and cells were removed by centrifugation at 1500× g, and fluids were cryopreserved in aliquots at −80 °C. The collection was approved by the local Ethical Committee, and all patients signed an informed consent.

4.8. Statistics

The concentrations of PD-L1, IL-6, and IL-27 reported as continuous variables were dichotomized on the basis of their median value. The association between PD-L1 concentration and IL-27 or IL-6 concentration was assessed using binomial logistic regressions. Odds ratio (OR) estimates, with 95% confidence intervals, were computed as a relative index of these associations. Overall survival (OS), as estimated from the date of pleural effusion withdrawal to the date of last contact or death from any cause, was analyzed using the Kaplan–Meier method, and differences between groups were assessed by the log-rank test.

5. Conclusions

In this report, we showed that the IL-6-related cytokine IL-27 mediates STAT1 signaling and PD-L1 gene and surface protein expression and sPD-L1 release by human MM cells in vitro. Conversely, IL-6 predominantly mediates STAT3 signaling but has no effect on PD-L1 expression. In addition, both IL-27 and sPD-L1 were present in pleural fluids from 77 MM patients and showed a relationship with worse overall survival. Finally, IL-27 levels showed a moderate albeit significant correlation with sPD-L1 concentration. Altogether, these data suggest a potential role of IL-27 in shaping PD-L1-mediated immune resistance in MM.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/cancers13164011/s1, Figure S1: Western blot analysis of tyrosine phosphorylated (p)STAT1, pSTAT3, total STAT1 and total STAT3 proteins in MSTO and MPP89 cells stimulated for 20 min with medium (CTR), IL-27 or IFN-γ. Figure S2: (A) Both IL-27 and IFN-γ upregulate PD-L1 molecule expression by malignant mesothelioma (MM) cells. (B) IL-27 upregulates MHC Class I molecule expression by MM cells. Figure S3: Analysis of IFN-γ levels in MM pleural exudates. Figure S4: Densitometric analyses of relevant bands (panels 4.1 to 4.3) and whole Western blot images (panels 4.4 to 4.12), relative to the figures indicated in each panel. Table S1: qRT-PCR primers. Table S2: Patient characteristics.

Author Contributions

Conceptualization, S.F. and M.F.; Data curation, G.C., S.M. and C.G.; Formal analysis, B.D. and M.F.; Funding acquisition, S.F., M.F. and G.C.; Investigation, G.C., B.D., M.C. and M.F.; Methodology, S.M.; Project administration, S.F., M.F. and G.C.; Resources, F.S.; Supervision, G.F., S.F. and M.F.; Validation, G.C., M.F. and B.D.; Visualization, M.F. and B.D.; Writing-original draft, S.F. and M.F.; Writing-review and editing, S.F., M.F., B.D. and M.C. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by grants from the Italian Ministry of Health (GR-2013-02356568, Ricerca Corrente and 5 × 1000 Funds).

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the authors’ Institutional Review Board (Comitato Etico Regionale, Regione Liguria, Study n. N9-13, ASL3. Regional platform id 4975, 21 July 2017).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study are contained within the article and supplementary materials.

Acknowledgments

We thank the Azienda Ospedaliera di Alessandria Biorepository “Alessandria Biobank” for providing the MM pleural effusions cohort.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Amin, W.; Linkov, F.; Landsittel, D.P.; Silverstein, J.C.; Bashara, W.; Gaudioso, C.; Feldman, M.D.; Pass, H.I.; Melamed, J.; Friedberg, J.S.; et al. Factors Influencing Malignant Mesothelioma Survival: A Retrospective Review of the National Mesothelioma Virtual Bank Cohort. F1000Research 2018, 7, 1184. [Google Scholar] [CrossRef]
  2. Maio, M.; Scherpereel, A.; Calabrò, L.; Aerts, J.; Perez, S.C.; Bearz, A.; Nackaerts, K.; Fennell, D.A.; Kowalski, D.; Tsao, A.S.; et al. Tremelimumab as Second-Line or Third-Line Treatment in Relapsed Malignant Mesothelioma (DETERMINE): A Multicentre, International, Randomised, Double-Blind, Placebo-Controlled Phase 2b Trial. Lancet Oncol. 2017, 18, 1261–1273. [Google Scholar] [CrossRef]
  3. Calabrò, L.; Morra, A.; Giannarelli, D.; Amato, G.; D’Incecco, A.; Covre, A.; Lewis, A.; Rebelatto, M.C.; Danielli, R.; Altomonte, M.; et al. Tremelimumab Combined with Durvalumab in Patients with Mesothelioma (NIBIT-MESO-1): An Open-Label, Non-Randomised, Phase 2 Study. Lancet Respir. Med. 2018, 6, 451–460. [Google Scholar] [CrossRef]
  4. Scherpereel, A.; Mazieres, J.; Greillier, L.; Lantuejoul, S.; Dô, P.; Bylicki, O.; Monnet, I.; Corre, R.; Audigier-Valette, C.; Locatelli-Sanchez, M.; et al. Nivolumab or Nivolumab plus Ipilimumab in Patients with Relapsed Malignant Pleural Mesothelioma (IFCT-1501 MAPS2): A Multicentre, Open-Label, Randomised, Non-Comparative, Phase 2 Trial. Lancet Oncol. 2019, 20, 239–253. [Google Scholar] [CrossRef]
  5. Hassan, R.; Thomas, A.; Nemunaitis, J.J.; Patel, M.R.; Bennouna, J.; Chen, F.L.; Delord, J.-P.; Dowlati, A.; Kochuparambil, S.T.; Taylor, M.H.; et al. Efficacy and Safety of Avelumab Treatment in Patients with Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019, 5, 351–357. [Google Scholar] [CrossRef]
  6. Metaxas, Y.; Rivalland, G.; Mauti, L.A.; Klingbiel, D.; Kao, S.; Schmid, S.; Nowak, A.K.; Gautschi, O.; Bartnick, T.; Hughes, B.G.; et al. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2018, 13, 1784–1791. [Google Scholar] [CrossRef] [Green Version]
  7. Fennell, D.A.; Kirkpatrick, E.; Cozens, K.; Nye, M.; Lester, J.; Hanna, G.; Steele, N.; Szlosarek, P.; Danson, S.; Lord, J.; et al. CONFIRM: A Double-Blind, Placebo-Controlled Phase III Clinical Trial Investigating the Effect of Nivolumab in Patients with Relapsed Mesothelioma: Study Protocol for a Randomised Controlled Trial. Trials 2018, 19, 233. [Google Scholar] [CrossRef] [Green Version]
  8. Alley, E.W.; Lopez, J.; Santoro, A.; Morosky, A.; Saraf, S.; Piperdi, B.; van Brummelen, E. Clinical Safety and Activity of Pembrolizumab in Patients with Malignant Pleural Mesothelioma (KEYNOTE-028): Preliminary Results from a Non-Randomised, Open-Label, Phase 1b Trial. Lancet Oncol. 2017, 18, 623–630. [Google Scholar] [CrossRef]
  9. Forde, P.M.; Scherpereel, A.; Tsao, A.S. Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr. Treat. Options Oncol. 2019, 20, 18. [Google Scholar] [CrossRef]
  10. Baas, P.; Scherpereel, A.; Nowak, A.K.; Fujimoto, N.; Peters, S.; Tsao, A.S.; Mansfield, A.S.; Popat, S.; Jahan, T.; Antonia, S.; et al. First-Line Nivolumab plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (CheckMate 743): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet 2021, 397, 375–386. [Google Scholar] [CrossRef]
  11. Brcic, L.; Klikovits, T.; Megyesfalvi, Z.; Mosleh, B.; Sinn, K.; Hritcu, R.; Laszlo, V.; Cufer, T.; Rozman, A.; Kern, I.; et al. Prognostic Impact of PD-1 and PD-L1 Expression in Malignant Pleural Mesothelioma: An International Multicenter Study. Transl. Lung Cancer Res. 2021, 10, 1594–1607. [Google Scholar] [CrossRef]
  12. Jin, L.; Gu, W.; Li, X.; Xie, L.; Wang, L.; Chen, Z. PD-L1 and Prognosis in Patients with Malignant Pleural Mesothelioma: A Meta-Analysis and Bioinformatics Study. Ther. Adv. Med. Oncol. 2020, 12, 1758835920962362. [Google Scholar] [CrossRef]
  13. Yang, H.; Rivera, Z.; Jube, S.; Nasu, M.; Bertino, P.; Goparaju, C.; Franzoso, G.; Lotze, M.T.; Krausz, T.; Pass, H.I.; et al. Programmed Necrosis Induced by Asbestos in Human Mesothelial Cells Causes High-Mobility Group Box 1 Protein Release and Resultant Inflammation. Proc. Natl. Acad. Sci. USA 2010, 107, 12611–12616. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Carbone, M.; Yang, H. Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma. Clin. Cancer Res. 2012, 18, 598–604. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Hillegass, J.M.; Miller, J.M.; MacPherson, M.B.; Westbom, C.M.; Sayan, M.; Thompson, J.K.; Macura, S.L.; Perkins, T.N.; Beuschel, S.L.; Alexeeva, V.; et al. Asbestos and Erionite Prime and Activate the NLRP3 Inflammasome That Stimulates Autocrine Cytokine Release in Human Mesothelial Cells. Part. Fibre Toxicol. 2013, 10, 39. [Google Scholar] [CrossRef] [Green Version]
  16. Comar, M.; Zanotta, N.; Zanconati, F.; Cortale, M.; Bonotti, A.; Cristaudo, A.; Bovenzi, M. Chemokines Involved in the Early Inflammatory Response and in Pro-Tumoral Activity in Asbestos-Exposed Workers from an Italian Coastal Area with Territorial Clusters of Pleural Malignant Mesothelioma. Lung Cancer 2016, 94, 61–67. [Google Scholar] [CrossRef] [PubMed]
  17. Judge, S.; Thomas, P.; Govindarajan, V.; Sharma, P.; Loggie, B. Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory Response in the Tumor Microenvironment. Ann. Surg. Oncol. 2016, 23, 1496–1500. [Google Scholar] [CrossRef] [PubMed]
  18. Rahim, S.N.A.; Ho, G.Y.; Coward, J.I.G. The Role of Interleukin-6 in Malignant Mesothelioma. Transl. Lung Cancer Res. 2015, 4, 55–66. [Google Scholar] [CrossRef]
  19. Nakano, T.; Chahinian, A.P.; Shinjo, M.; Tonomura, A.; Miyake, M.; Togawa, N.; Ninomiya, K.; Higashino, K. Interleukin 6 and Its Relationship to Clinical Parameters in Patients with Malignant Pleural Mesothelioma. Br. J. Cancer 1998, 77, 907–912. [Google Scholar] [CrossRef] [Green Version]
  20. Monti, G.; Jaurand, M.C.; Monnet, I.; Chretien, P.; Saint-Etienne, L.; Zeng, L.; Portier, A.; Devillier, P.; Galanaud, P.; Bignon, J. Intrapleural Production of Interleukin 6 during Mesothelioma and Its Modulation by Gamma-Interferon Treatment. Cancer Res. 1994, 54, 4419–4423. [Google Scholar]
  21. Rose-John, S.; Neurath, M.F. IL-6 Trans-Signaling: The Heat Is On. Immunity 2004, 20, 2–4. [Google Scholar] [CrossRef] [Green Version]
  22. Adachi, Y.; Aoki, C.; Yoshio-Hoshino, N.; Takayama, K.; Curiel, D.T.; Nishimoto, N. Interleukin-6 Induces Both Cell Growth and VEGF Production in Malignant Mesotheliomas. Int. J. Cancer 2006, 119, 1303–1311. [Google Scholar] [CrossRef]
  23. Lamano, J.B.; Lamano, J.B.; Li, Y.D.; DiDomenico, J.D.; Choy, W.; Veliceasa, D.; Oyon, D.E.; Fakurnejad, S.; Ampie, L.; Kesavabhotla, K.; et al. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth. Clin. Cancer Res. 2019, 25, 3643–3657. [Google Scholar] [CrossRef] [Green Version]
  24. Tamura, H.; Ishibashi, M.; Yamashita, T.; Tanosaki, S.; Okuyama, N.; Kondo, A.; Hyodo, H.; Shinya, E.; Takahashi, H.; Dong, H.; et al. Marrow Stromal Cells Induce B7-H1 Expression on Myeloma Cells, Generating Aggressive Characteristics in Multiple Myeloma. Leukemia 2013, 27, 464–472. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Jones, S.A.; Jenkins, B.J. Recent Insights into Targeting the IL-6 Cytokine Family in Inflammatory Diseases and Cancer. Nat. Rev. Immunol. 2018, 18, 773–789. [Google Scholar] [CrossRef]
  26. Rose-John, S. Interleukin-6 Family Cytokines. Cold Spring Harb. Perspect. Biol. 2018, 10, a028415. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Fabbi, M.; Carbotti, G.; Ferrini, S. Dual Roles of IL-27 in Cancer Biology and Immunotherapy. Mediat. Inflamm. 2017, 2017, 3958069. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  28. Tait Wojno, E.D.; Hunter, C.A.; Stumhofer, J.S. The Immunobiology of the Interleukin-12 Family: Room for Discovery. Immunity 2019, 50, 851–870. [Google Scholar] [CrossRef]
  29. Mirlekar, B.; Pylayeva-Gupta, Y. IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers 2021, 13, 167. [Google Scholar] [CrossRef]
  30. Pflanz, S.; Timans, J.C.; Cheung, J.; Rosales, R.; Kanzler, H.; Gilbert, J.; Hibbert, L.; Churakova, T.; Travis, M.; Vaisberg, E.; et al. IL-27, a Heterodimeric Cytokine Composed of EBI3 and P28 Protein, Induces Proliferation of Naive CD4+ T Cells. Immunity 2002, 16, 779–790. [Google Scholar] [CrossRef] [Green Version]
  31. Petretto, A.; Carbotti, G.; Inglese, E.; Lavarello, C.; Pistillo, M.P.; Rigo, V.; Croce, M.; Longo, L.; Martini, S.; Vacca, P.; et al. Proteomic Analysis Uncovers Common Effects of IFN-γ and IL-27 on the HLA Class I Antigen Presentation Machinery in Human Cancer Cells. Oncotarget 2016, 7, 72518–72536. [Google Scholar] [CrossRef] [Green Version]
  32. Airoldi, I.; Ribatti, D. Regulation of Angiostatic Chemokines Driven by IL-12 and IL-27 in Human Tumors. J. Leukoc. Biol. 2011, 90, 875–882. [Google Scholar] [CrossRef] [PubMed]
  33. Bender, H.; Wiesinger, M.Y.; Nordhoff, C.; Schoenherr, C.; Haan, C.; Ludwig, S.; Weiskirchen, R.; Kato, N.; Heinrich, P.C.; Haan, S. Interleukin-27 Displays Interferon-Gamma-like Functions in Human Hepatoma Cells and Hepatocytes. Hepatology 2009, 50, 585–591. [Google Scholar] [CrossRef]
  34. Feng, X.M.; Liu, N.; Yang, S.G.; Hu, L.Y.; Chen, X.L.; Fang, Z.H.; Ren, Q.; Lu, S.H.; Liu, B.; Han, Z.C. Regulation of the Class II and Class I MHC Pathways in Human THP-1 Monocytic Cells by Interleukin-27. Biochem. Biophys. Res. Commun. 2008, 367, 553–559. [Google Scholar] [CrossRef] [PubMed]
  35. Carbotti, G.; Nikpoor, A.R.; Vacca, P.; Gangemi, R.; Giordano, C.; Campelli, F.; Ferrini, S.; Fabbi, M. IL-27 Mediates HLA Class I up-Regulation, Which Can Be Inhibited by the IL-6 Pathway, in HLA-Deficient Small Cell Lung Cancer Cells. J. Exp. Clin. Cancer Res. 2017, 36, 140. [Google Scholar] [CrossRef] [Green Version]
  36. Di Carlo, E.; Sorrentino, C.; Zorzoli, A.; Di Meo, S.; Tupone, M.G.; Ognio, E.; Mincione, G.; Airoldi, I. The Antitumor Potential of Interleukin-27 in Prostate Cancer. Oncotarget 2014, 5, 10332–10341. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Yoshimoto, T.; Morishima, N.; Mizoguchi, I.; Shimizu, M.; Nagai, H.; Oniki, S.; Oka, M.; Nishigori, C.; Mizuguchi, J. Antiproliferative Activity of IL-27 on Melanoma. J. Immunol. 2008, 180, 6527–6535. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  38. Spranger, S.; Spaapen, R.M.; Zha, Y.; Williams, J.; Meng, Y.; Ha, T.T.; Gajewski, T.F. Up-Regulation of PD-L1, IDO, and T(Regs) in the Melanoma Tumor Microenvironment Is Driven by CD8(+) T Cells. Sci. Transl. Med. 2013, 5, 200ra116. [Google Scholar] [CrossRef] [Green Version]
  39. Lee, S.-J.; Jang, B.-C.; Lee, S.-W.; Yang, Y.-I.; Suh, S.-I.; Park, Y.-M.; Oh, S.; Shin, J.-G.; Yao, S.; Chen, L.; et al. Interferon Regulatory Factor-1 Is Prerequisite to the Constitutive Expression and IFN-Gamma-Induced Upregulation of B7-H1 (CD274). FEBS Lett. 2006, 580, 755–762. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  40. Carbotti, G.; Barisione, G.; Airoldi, I.; Mezzanzanica, D.; Bagnoli, M.; Ferrero, S.; Petretto, A.; Fabbi, M.; Ferrini, S. IL-27 Induces the Expression of IDO and PD-L1 in Human Cancer Cells. Oncotarget 2015, 6, 43267–43280. [Google Scholar] [CrossRef] [Green Version]
  41. Dozin, B.; Carbotti, G.; Roncella, S.; Ferro, P.; Dessanti, P.; Canessa, P.A.; Ferrini, S.; Fabbi, M. Assessment of Interferon-γ in Pleural Fluid as a Prognostic Factor of Survival in Malignant Pleural Mesothelioma. Cancer Immunol. Immunother. 2021. [Google Scholar] [CrossRef]
  42. Kondo, A.; Yamashita, T.; Tamura, H.; Zhao, W.; Tsuji, T.; Shimizu, M.; Shinya, E.; Takahashi, H.; Tamada, K.; Chen, L.; et al. Interferon-Gamma and Tumor Necrosis Factor-Alpha Induce an Immunoinhibitory Molecule, B7-H1, via Nuclear Factor-KappaB Activation in Blasts in Myelodysplastic Syndromes. Blood 2010, 116, 1124–1131. [Google Scholar] [CrossRef] [Green Version]
  43. Pistillo, M.P.; Carosio, R.; Banelli, B.; Morabito, A.; Mastracci, L.; Ferro, P.; Varesano, S.; Venè, R.; Poggi, A.; Roncella, S. IFN-γ Upregulates Membranous and Soluble PD-L1 in Mesothelioma Cells: Potential Implications for the Clinical Response to PD-1/PD-L1 Blockade. Cell. Mol. Immunol. 2020, 17, 410–411. [Google Scholar] [CrossRef]
  44. Carbotti, G.; Petretto, A.; Naschberger, E.; Stürzl, M.; Martini, S.; Mingari, M.C.; Filaci, G.; Ferrini, S.; Fabbi, M. Cytokine-Induced Guanylate Binding Protein 1 (GBP1) Release from Human Ovarian Cancer Cells. Cancers 2020, 12, 488. [Google Scholar] [CrossRef] [Green Version]
  45. Carosio, R.; Fontana, V.; Mastracci, L.; Ferro, P.; Grillo, F.; Banelli, B.; Canessa, P.A.; Dessanti, P.; Vigani, A.; Morabito, A.; et al. Characterization of Soluble PD-L1 in Pleural Effusions of Mesothelioma Patients: Potential Implications in the Immune Response and Prognosis. J. Cancer Res. Clin. Oncol. 2021, 147, 459–468. [Google Scholar] [CrossRef] [PubMed]
  46. Christmas, T.I.; Manning, L.S.; Davis, M.R.; Robinson, B.W.; Garlepp, M.J. HLA Antigen Expression and Malignant Mesothelioma. Am. J. Respir. Cell. Mol. Biol. 1991, 5, 213–220. [Google Scholar] [CrossRef]
  47. Mutti, L.; Valle, M.T.; Balbi, B.; Orengo, A.M.; Lazzaro, A.; Alciato, P.; Gatti, E.; Betta, P.G.; Pozzi, E. Primary Human Mesothelioma Cells Express Class II MHC, ICAM-1 and B7-2 and Can Present Recall Antigens to Autologous Blood Lymphocytes. Int. J. Cancer 1998, 78, 740–749. [Google Scholar] [CrossRef]
  48. Orengo, A.M.; Spoletini, L.; Procopio, A.; Favoni, R.E.; De Cupis, A.; Ardizzoni, A.; Castagneto, B.; Ribotta, M.; Betta, P.G.; Ferrini, S.; et al. Establishment of Four New Mesothelioma Cell Lines: Characterization by Ultrastructural and Immunophenotypic Analysis. Eur. Respir. J. 1999, 13, 527–534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  49. Tumeh, P.C.; Harview, C.L.; Yearley, J.H.; Shintaku, I.P.; Taylor, E.J.M.; Robert, L.; Chmielowski, B.; Spasic, M.; Henry, G.; Ciobanu, V.; et al. PD-1 Blockade Induces Responses by Inhibiting Adaptive Immune Resistance. Nature 2014, 515, 568–571. [Google Scholar] [CrossRef]
  50. Ribas, A. Adaptive Immune Resistance: How Cancer Protects from Immune Attack. Cancer Discov. 2015, 5, 915–919. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Awasthi, A.; Carrier, Y.; Peron, J.P.S.; Bettelli, E.; Kamanaka, M.; Flavell, R.A.; Kuchroo, V.K.; Oukka, M.; Weiner, H.L. A Dominant Function for Interleukin 27 in Generating Interleukin 10-Producing Anti-Inflammatory T Cells. Nat. Immunol. 2007, 8, 1380–1389. [Google Scholar] [CrossRef]
  52. Yi, J.; Chen, Z.; Xu, F.; Wang, Z.; Zhang, A.; Liu, T.; Zhao, N.; Xiong, Y.; Jiang, G.; Ma, J.; et al. IL-27 Promotes Human Placenta-Derived Mesenchymal Stromal Cell Ability To Induce the Generation of CD4+IL-10+IFN-Γ+ T Cells via the JAK/STAT Pathway in the Treatment of Experimental Graft-versus-Host Disease. J. Immunol. 2019, 202, 1124–1136. [Google Scholar] [CrossRef]
  53. Meka, R.R.; Venkatesha, S.H.; Dudics, S.; Acharya, B.; Moudgil, K.D. IL-27-Induced Modulation of Autoimmunity and Its Therapeutic Potential. Autoimmun. Rev. 2015, 14, 1131–1141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Pot, C.; Apetoh, L.; Awasthi, A.; Kuchroo, V.K. Induction of Regulatory Tr1 Cells and Inhibition of TH17 Cells by IL-27. Semin. Immunol. 2011, 23, 438–445. [Google Scholar] [CrossRef] [Green Version]
  55. DeLong, J.H.; Hall, A.; Rausch, M.; Moodley, D.; Perry, J.; Park, J.; Phan, A.T.; Beiting, D.P.; Kedl, R.M.; Hill, J.A.; et al. IL-27 and TCR Stimulation Promote T Cell Expression of Multiple Inhibitory Receptors. Immunohorizons 2019, 3, 13–25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Orme, J.J.; Jazieh, K.A.; Xie, T.; Harrington, S.; Liu, X.; Ball, M.; Madden, B.; Charlesworth, M.C.; Azam, T.U.; Lucien, F.; et al. ADAM10 and ADAM17 Cleave PD-L1 to Mediate PD-(L)1 Inhibitor Resistance. OncoImmunology 2020, 9, 1744980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Romero, Y.; Wise, R.; Zolkiewska, A. Proteolytic Processing of PD-L1 by ADAM Proteases in Breast Cancer Cells. Cancer Immunol. Immunother. 2020, 69, 43–55. [Google Scholar] [CrossRef]
  58. Mahoney, K.M.; Shukla, S.A.; Patsoukis, N.; Chaudhri, A.; Browne, E.P.; Arazi, A.; Eisenhaure, T.M.; Pendergraft, W.F.; Hua, P.; Pham, H.C.; et al. A Secreted PD-L1 Splice Variant That Covalently Dimerizes and Mediates Immunosuppression. Cancer Immunol. Immunother. 2019, 68, 421–432. [Google Scholar] [CrossRef] [Green Version]
  59. Hassounah, N.B.; Malladi, V.S.; Huang, Y.; Freeman, S.S.; Beauchamp, E.M.; Koyama, S.; Souders, N.; Martin, S.; Dranoff, G.; Wong, K.-K.; et al. Identification and Characterization of an Alternative Cancer-Derived PD-L1 Splice Variant. Cancer Immunol. Immunother. 2019, 68, 407–420. [Google Scholar] [CrossRef] [PubMed]
  60. Frigola, X.; Inman, B.A.; Lohse, C.M.; Krco, C.J.; Cheville, J.C.; Thompson, R.H.; Leibovich, B.; Blute, M.L.; Dong, H.; Kwon, E.D. Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma. Clin. Cancer Res. 2011, 17, 1915–1923. [Google Scholar] [CrossRef] [Green Version]
  61. Gong, B.; Kiyotani, K.; Sakata, S.; Nagano, S.; Kumehara, S.; Baba, S.; Besse, B.; Yanagitani, N.; Friboulet, L.; Nishio, M.; et al. Secreted PD-L1 Variants Mediate Resistance to PD-L1 Blockade Therapy in Non-Small Cell Lung Cancer. J. Exp. Med. 2019, 216, 982–1000. [Google Scholar] [CrossRef] [Green Version]
  62. Jiang, Y.; Chen, M.; Nie, H.; Yuan, Y. PD-1 and PD-L1 in Cancer Immunotherapy: Clinical Implications and Future Considerations. Hum. Vaccines Immunother. 2019, 15, 1111–1122. [Google Scholar] [CrossRef]
  63. Wu, Y.; Chen, W.; Xu, Z.P.; Gu, W. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition. Front. Immunol. 2019, 10, 2022. [Google Scholar] [CrossRef] [Green Version]
  64. Khanna, S.; Thomas, A.; Abate-Daga, D.; Zhang, J.; Morrow, B.; Steinberg, S.M.; Orlandi, A.; Ferroni, P.; Schlom, J.; Guadagni, F.; et al. Malignant Mesothelioma Effusions Are Infiltrated by CD3+ T Cells Highly Expressing PD-L1 and the PD-L1+ Tumor Cells within These Effusions Are Susceptible to ADCC by the Anti-PD-L1 Antibody Avelumab. J. Thorac. Oncol. 2016, 11, 1993–2005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Boyerinas, B.; Jochems, C.; Fantini, M.; Heery, C.R.; Gulley, J.L.; Tsang, K.Y.; Schlom, J. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti–PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol. Res. 2015, 3, 1148–1157. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Jia, H.; Dilger, P.; Bird, C.; Wadhwa, M. IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs. J. Interferon Cytokine Res. 2016, 36, 302–316. [Google Scholar] [CrossRef] [Green Version]
  67. Molle, C.; Nguyen, M.; Flamand, V.; Renneson, J.; Trottein, F.; De Wit, D.; Willems, F.; Goldman, M.; Goriely, S. IL-27 Synthesis Induced by TLR Ligation Critically Depends on IFN Regulatory Factor 3. J. Immunol. 2007, 178, 7607–7615. [Google Scholar] [CrossRef] [Green Version]
  68. Murakami, M.; Kamimura, D.; Hirano, T. Pleiotropy and Specificity: Insights from the Interleukin 6 Family of Cytokines. Immunity 2019, 50, 812–831. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Cancers 13 04011 g001 550
Figure 1. IL-27 predominantly mediates STAT1 phosphorylation in MM cell lines. Western blot analysis of tyrosine phosphorylated (P)-STAT1, P-STAT3, total STAT1 and total STAT3 proteins (A) in MPP89 cells stimulated for 20 min with medium (CTR) or the indicated cytokines of the IL-12 family and (B) in MSTO, MPP89, and IST-MES1 cells stimulated for 20 min with medium (CTR), IL-6, sIL-6R/IL-6 chimera, and IL-27. Total STATs and α-tubulin were used as loading controls.
Figure 1. IL-27 predominantly mediates STAT1 phosphorylation in MM cell lines. Western blot analysis of tyrosine phosphorylated (P)-STAT1, P-STAT3, total STAT1 and total STAT3 proteins (A) in MPP89 cells stimulated for 20 min with medium (CTR) or the indicated cytokines of the IL-12 family and (B) in MSTO, MPP89, and IST-MES1 cells stimulated for 20 min with medium (CTR), IL-6, sIL-6R/IL-6 chimera, and IL-27. Total STATs and α-tubulin were used as loading controls.
Cancers 13 04011 g001
Cancers 13 04011 g002 550
Figure 2. IL-27 upregulates PD-L1 molecule expression and release by MM cells. (A) Flow cytometry analysis of membrane PD-L1 expression in MSTO, MPP89, and IST-MES1 MM cell lines cultured with medium alone (baseline), IL-6, sIL-6R/IL-6 chimera, or IL-27 (induced). Dotted line shows isotype-matched Ig control. Numbers in brackets represent Median Fluorescence Intensity (MFI) values calculated as median anti-PD-L1 mAb minus median Ig control. Data are representative of two independent experiments yielding similar results. (B) qRT-PCR analysis of CD274 (PD-L1) mRNA expression in the same three MM cell lines stimulated with IL-6, sIL-6R/IL-6 chimera, IL-27, or IFN-γ relative to untreated cells. Data are calculated with the ΔΔCT method and expressed as fold change versus untreated control. Error bars represent SD of triplicates. LGALS3 (Galectin 3) and GBP1 (Guanylate Binding Protein 1) mRNA levels are shown, respectively, as negative and positive controls of IL-27 activity. (C) Evaluation by ELISA of soluble (s)PD-L1 release in the conditioned media of the indicated MM cells treated with IL-6, sIL-6R/IL-6 chimera, or IL-27. Data are expressed as a percent of untreated control and are the mean of two independent experiments, run in duplicates. Error bars represent the minimum and maximum values (* p < 0.001, Student’s t-test versus untreated control).
Figure 2. IL-27 upregulates PD-L1 molecule expression and release by MM cells. (A) Flow cytometry analysis of membrane PD-L1 expression in MSTO, MPP89, and IST-MES1 MM cell lines cultured with medium alone (baseline), IL-6, sIL-6R/IL-6 chimera, or IL-27 (induced). Dotted line shows isotype-matched Ig control. Numbers in brackets represent Median Fluorescence Intensity (MFI) values calculated as median anti-PD-L1 mAb minus median Ig control. Data are representative of two independent experiments yielding similar results. (B) qRT-PCR analysis of CD274 (PD-L1) mRNA expression in the same three MM cell lines stimulated with IL-6, sIL-6R/IL-6 chimera, IL-27, or IFN-γ relative to untreated cells. Data are calculated with the ΔΔCT method and expressed as fold change versus untreated control. Error bars represent SD of triplicates. LGALS3 (Galectin 3) and GBP1 (Guanylate Binding Protein 1) mRNA levels are shown, respectively, as negative and positive controls of IL-27 activity. (C) Evaluation by ELISA of soluble (s)PD-L1 release in the conditioned media of the indicated MM cells treated with IL-6, sIL-6R/IL-6 chimera, or IL-27. Data are expressed as a percent of untreated control and are the mean of two independent experiments, run in duplicates. Error bars represent the minimum and maximum values (* p < 0.001, Student’s t-test versus untreated control).
Cancers 13 04011 g002
Cancers 13 04011 g003 550
Figure 3. IL-27 is detectable in MM pleural exudates and correlates with sPD-L1 expression. (A) Concentration (pg/mL) of sPD-L1, IL-27, and IL-6 in pleural effusion. Bars indicate median values. (B) Correlation between IL-27 and sPD-L1 levels in MM pleural fluids. Spearman’s rank correlation coefficient (R) and p-value (P) are indicated. Lines represent the best fit linear regression analysis with the 95% confidence interval.
Figure 3. IL-27 is detectable in MM pleural exudates and correlates with sPD-L1 expression. (A) Concentration (pg/mL) of sPD-L1, IL-27, and IL-6 in pleural effusion. Bars indicate median values. (B) Correlation between IL-27 and sPD-L1 levels in MM pleural fluids. Spearman’s rank correlation coefficient (R) and p-value (P) are indicated. Lines represent the best fit linear regression analysis with the 95% confidence interval.
Cancers 13 04011 g003
Cancers 13 04011 g004 550
Figure 4. Kaplan–Meier curves assessing overall survival according to sPD-L1, IL-27, and IL-6 concentrations in the pleural effusion, as dichotomized around their respective median value. Analyses with respect to all cases (n = 77) (panels A–C) and the subgroup with the epithelioid histotype (n = 55) (panels D–F) are shown.
Figure 4. Kaplan–Meier curves assessing overall survival according to sPD-L1, IL-27, and IL-6 concentrations in the pleural effusion, as dichotomized around their respective median value. Analyses with respect to all cases (n = 77) (panels A–C) and the subgroup with the epithelioid histotype (n = 55) (panels D–F) are shown.
Cancers 13 04011 g004
Table
Table 1. Association of sPD-L1 concentration with IL-27 and IL-6 concentrations.
Table 1. Association of sPD-L1 concentration with IL-27 and IL-6 concentrations.
TotalsPD-L1 ≥ 166.2 pg/mL
N%OR *95% CI p-Value
IL-27 < 0.358 ng/mL381230.81 (ref)-0.001
IL-27 ≥ 0.358 ng/mL392769.24.861.86–12.79
IL-6 < 1683.5 pg/mL392051.31 (ref)-0.910
IL-6 ≥ 1683.5 pg/mL381948.70.9500.39–2.32
* OR, odds ratio. 95% CI, 95% confidence intervals.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Carbotti, G.; Dozin, B.; Martini, S.; Giordano, C.; Scordamaglia, F.; Croce, M.; Filaci, G.; Ferrini, S.; Fabbi, M. IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells. Cancers 2021, 13, 4011. https://doi.org/10.3390/cancers13164011

AMA Style

Carbotti G, Dozin B, Martini S, Giordano C, Scordamaglia F, Croce M, Filaci G, Ferrini S, Fabbi M. IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells. Cancers. 2021; 13(16):4011. https://doi.org/10.3390/cancers13164011

Chicago/Turabian Style

Carbotti, Grazia, Beatrice Dozin, Stefania Martini, Chiara Giordano, Francesca Scordamaglia, Michela Croce, Gilberto Filaci, Silvano Ferrini, and Marina Fabbi. 2021. "IL-27 Mediates PD-L1 Expression and Release by Human Mesothelioma Cells" Cancers 13, no. 16: 4011. https://doi.org/10.3390/cancers13164011

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop